<DOC>
	<DOCNO>NCT00981747</DOCNO>
	<brief_summary>The purpose study determine whether combination therapy sildenafil losartan improve function exercise tolerance patient idiopathic pulmonary fibrosis .</brief_summary>
	<brief_title>Targeting Vascular Reactivity Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Age 1899 Have take study medication past 6 week Diagnosed idiopathic pulmonary fibrosis FVC &lt; 50 % , DLco &lt; 30 % FEV1/FVC ratio &lt; 65 % Greater amount emphysema fibrotic change chest CT scan Acute myocardial infarction within past 6 month Nitrate use Contraindications , hypersensitivity , allergic reaction study medication Presence aortic stenosis Lifethreatening arrhythmia within 1 month evaluation Diabetes require insulin therapy Seconddegree thirddegree atrioventricular block electrocardiogram Echocardiographic evidence severe pulmonary hypertension ( &gt; 50mmHg ) â€¢ Severe terminal illness ( survival predict less 1 year ) Severe congestive heart failure Renal impairment ( creatinine &gt; 2.0 mg/dl ) Moderate severe hepatic impairment Concurrent treatment immunosuppressive , cytotoxic , investigational agent . Pregnant Breastfeeding ( Women childbearing age must use effective form birth control abstinence study participation ) History acute exacerbation IPF Current enrollment another investigational protocol Acute chronic impairment dyspnea limit patient 's ability perform six minute walk test Current drug alcohol dependence Initiation pulmonary rehabilitation within 30 day enrollment . Subjects currently undergo maintenance pulmonary rehabilitation study entry ask maintain level rehabilitation duration trial Treatment pulmonary hypertension prostaglandin , endothelin1 antagonist , phosphodiesterase inhibitor within 30 day enrollment Addition discontinuation calcium channel blocker , digitalis , diuretic vasodilator within 30 day enrollment . Dosage must stable 7 day prior enrollment ( except diuretic ) Listed lung transplantation Due drug interaction , follow agent prohibit : alphablockers , endothelin1 antagonist , CYP3A4 inhibitor Resting oxygen saturation &lt; 92 % great 6 liter supplemental oxygen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>